Symbols / MLYS Stock $28.65 -0.97% Mineralys Therapeutics, Inc.

Healthcare • Biotechnology • United States • NMS
MLYS (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
About

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Stock Fundamentals
Scroll to Statements
Market Cap 2.36B Enterprise Value 1.73B Income -154.65M Sales — Book/sh 7.93 Cash/sh 7.97
Dividend Yield — Payout 0.00% Employees 76 IPO — P/E — Forward P/E -15.66
PEG — P/S — P/B 3.61 P/C — EV/EBITDA -10.13 EV/Sales —
Quick Ratio 43.45 Current Ratio 43.76 Debt/Eq — LT Debt/Eq — EPS (ttm) -2.29 EPS next Y -1.83
EPS Growth — Revenue Growth — Earnings 2026-05-12 ROA -24.58% ROE -36.91% ROIC —
Gross Margin 0.00% Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 82.45M Shs Float 60.26M Short Float 12.33%
Short Ratio 5.86 Short Interest — 52W High 47.65 52W Low 12.59 Beta 0.69 Avg Volume 1.23M
Volume 175.28K Target Price $49.38 Recom None Prev Close $28.93 Price $28.65 Change -0.97%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$49.38
Mean price target
2. Current target
$28.65
Latest analyst target
3. DCF / Fair value
$-18.42
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$28.65
Low
$30.00
High
$56.00
Mean
$49.38

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-13 main B of A Securities Buy → Buy $51
2025-12-19 main Stifel Buy → Buy $52
2025-11-12 main HC Wainwright & Co. Buy → Buy $56
2025-11-11 main Wells Fargo Overweight → Overweight $55
2025-10-30 main HC Wainwright & Co. Buy → Buy $52
2025-09-11 main Wells Fargo Overweight → Overweight $50
2025-09-09 main Goldman Sachs Buy → Buy $52
2025-09-08 reit HC Wainwright & Co. Buy → Buy $42
2025-09-03 main Jefferies Hold → Hold $26
2025-08-28 main B of A Securities Buy → Buy $43
2025-08-13 reit HC Wainwright & Co. Buy → Buy $42
2025-06-17 reit HC Wainwright & Co. Buy → Buy $42
2025-06-11 init Jefferies — → Hold $15
2025-05-13 reit HC Wainwright & Co. Buy → Buy $42
2025-04-02 main HC Wainwright & Co. Buy → Buy $42
2025-03-10 reit HC Wainwright & Co. Buy → Buy $30
2025-02-24 reit Guggenheim Buy → Buy —
2025-02-13 main Goldman Sachs Buy → Buy $24
2025-02-13 reit HC Wainwright & Co. Buy → Buy $30
2024-11-12 reit HC Wainwright & Co. Buy → Buy $30
News
RSS: Latest MLYS news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-17 RODMAN DAVID MALCOM Officer — 416 $31.33 $13,033
2026-04-17 RODMAN DAVID MALCOM Officer — 416 $15.44 $6,423
2026-04-15 RODMAN DAVID MALCOM Officer — 20,406 $26.54 $548,672
2026-04-13 CONGLETON JON Chief Executive Officer — 15,730 $26.83 $421,979
2026-04-13 RODMAN DAVID MALCOM Officer — 14,058 $1.08 $102,365
2026-04-09 RODMAN DAVID MALCOM Officer — 2,170 $27.38 $59,415
2026-04-09 RODMAN DAVID MALCOM Officer — 2,170 $16.00 $34,720
2026-03-31 KARYDAS DAPHNE Director — 3,000 $25.00 $75,000
2026-03-31 KARYDAS DAPHNE Director — 3,000 $12.02 $36,060
2026-03-31 CONGLETON JON Chief Executive Officer — 75,000 $25.50 $1,970,522
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
170.60
-11.33%
192.40
+127.27%
84.66
+168.93%
31.48
Research And Development
132.01
-21.69%
168.58
+139.59%
70.36
+168.04%
26.25
Selling General And Administration
38.59
+62.01%
23.82
+66.63%
14.30
+173.40%
5.23
General And Administrative Expense
38.59
+62.01%
23.82
+66.63%
14.30
+173.40%
5.23
Other Gand A
38.59
+62.01%
23.82
+66.63%
14.30
+173.40%
5.23
Total Expenses
170.60
-11.33%
192.40
+127.27%
84.66
+168.93%
31.48
Operating Income
-170.60
+11.33%
-192.40
-127.27%
-84.66
-168.93%
-31.48
Total Operating Income As Reported
-170.60
+11.33%
-192.40
-127.27%
-84.66
-168.93%
-31.48
EBITDA
-170.54
+11.34%
-192.36
-127.22%
-84.66
-168.93%
-31.48
Normalized EBITDA
-170.54
+11.34%
-192.36
-127.22%
-84.66
-168.93%
-31.48
Reconciled Depreciation
0.06
+37.21%
0.04
0.00
—
EBIT
-170.60
+11.33%
-192.40
-127.27%
-84.66
-168.93%
-31.48
Total Unusual Items
—
—
—
—
Total Unusual Items Excluding Goodwill
—
—
—
—
Net Income
-154.65
+13.02%
-177.81
-147.31%
-71.90
-141.28%
-29.80
Pretax Income
-154.65
+13.02%
-177.81
-147.31%
-71.90
-141.28%
-29.80
Net Non Operating Interest Income Expense
15.95
+9.36%
14.59
+14.36%
12.76
+661.10%
1.68
Interest Expense Non Operating
—
—
—
—
Net Interest Income
15.95
+9.36%
14.59
+14.36%
12.76
+661.10%
1.68
Interest Expense
—
—
—
—
Interest Income Non Operating
15.95
+9.36%
14.59
+14.36%
12.76
+661.10%
1.68
Interest Income
15.95
+9.36%
14.59
+14.36%
12.76
+661.10%
1.68
Other Income Expense
—
0.01
+66.67%
0.00
-25.00%
0.00
Other Non Operating Income Expenses
—
0.01
+66.67%
0.00
-25.00%
0.00
Gain On Sale Of Security
—
—
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-154.65
+13.02%
-177.81
-147.31%
-71.90
-141.28%
-29.80
Net Income From Continuing Operation Net Minority Interest
-154.65
+13.02%
-177.81
-147.31%
-71.90
-141.28%
-29.80
Net Income From Continuing And Discontinued Operation
-154.65
+13.02%
-177.81
-147.31%
-71.90
-141.28%
-29.80
Net Income Continuous Operations
-154.65
+13.02%
-177.81
-147.31%
-71.90
-141.28%
-29.80
Normalized Income
-154.65
+13.02%
-177.81
-147.31%
-71.90
-141.28%
-29.80
Net Income Common Stockholders
-154.65
+13.02%
-177.81
-147.31%
-71.90
-141.28%
-29.80
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
—
-3.66
-83.92%
-1.99
-160.82%
-0.76
Basic EPS
—
-3.66
-83.92%
-1.99
-160.82%
-0.76
Basic Average Shares
—
48.54
+34.13%
36.19
-7.34%
39.06
Diluted Average Shares
—
48.54
+34.13%
36.19
-7.34%
39.06
Diluted NI Availto Com Stockholders
-154.65
+13.02%
-177.81
-147.31%
-71.90
-141.28%
-29.80
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
661.81
+221.42%
205.90
-18.17%
251.64
+119.88%
114.44
Current Assets
661.39
+222.08%
205.35
-17.56%
249.10
+120.81%
112.81
Cash Cash Equivalents And Short Term Investments
656.63
+231.32%
198.19
-16.22%
236.57
+114.85%
110.11
Cash And Cash Equivalents
172.92
+51.56%
114.09
+131.40%
49.30
-43.78%
87.70
Cash Equivalents
171.89
+51.54%
113.43
+133.10%
48.66
-42.64%
84.83
Cash Financial
1.03
+55.12%
0.66
+3.27%
0.64
-77.61%
2.87
Other Short Term Investments
483.71
+475.19%
84.10
-55.09%
187.26
+735.66%
22.41
Prepaid Assets
—
—
—
—
Other Current Assets
4.75
-33.68%
7.16
-42.85%
12.54
+364.12%
2.70
Total Non Current Assets
0.42
-23.91%
0.55
-78.21%
2.53
+55.30%
1.63
Net PPE
0.04
-28.30%
0.05
0.00
—
Investments And Advances
—
0.00
-100.00%
2.48
0.00
Other Investments
—
0.00
-100.00%
2.48
0.00
Non Current Deferred Assets
—
—
0.05
-96.87%
1.63
Other Non Current Assets
0.38
-23.45%
0.50
+878.43%
0.05
—
Total Liabilities Net Minority Interest
15.11
+3.19%
14.65
+39.73%
10.48
-93.71%
166.71
Current Liabilities
15.11
+3.19%
14.65
+39.73%
10.48
+29.94%
8.07
Payables And Accrued Expenses
9.57
-13.48%
11.06
+24.55%
8.88
+20.01%
7.40
Payables
2.02
+321.09%
0.48
-20.30%
0.60
-68.48%
1.91
Accounts Payable
2.02
+321.09%
0.48
-20.30%
0.60
-68.48%
1.91
Current Accrued Expenses
7.56
-28.62%
10.59
+27.81%
8.28
+50.72%
5.50
Pensionand Other Post Retirement Benefit Plans Current
5.54
+54.66%
3.58
+124.02%
1.60
+140.45%
0.67
Total Non Current Liabilities Net Minority Interest
0.00
0.00
0.00
-100.00%
158.64
Preferred Securities Outside Stock Equity
—
0.00
0.00
-100.00%
158.64
Stockholders Equity
646.69
+238.13%
191.26
-20.69%
241.15
+561.37%
-52.27
Common Stock Equity
646.69
+238.13%
191.26
-20.69%
241.15
+561.37%
-52.27
Capital Stock
0.01
+60.00%
0.01
+25.00%
0.00
+300.00%
0.00
Common Stock
0.01
+60.00%
0.01
+25.00%
0.00
+300.00%
0.00
Preferred Stock
—
—
—
—
Share Issued
81.54
+63.66%
49.82
+21.12%
41.13
+5.32%
39.06
Ordinary Shares Number
81.54
+63.66%
49.82
+21.12%
41.13
+5.32%
39.06
Additional Paid In Capital
1,103.85
+123.56%
493.77
+34.96%
365.86
+67651.48%
0.54
Retained Earnings
-457.17
-51.12%
-302.52
-142.58%
-124.71
-136.14%
-52.81
Total Equity Gross Minority Interest
646.69
+238.13%
191.26
-20.69%
241.15
+561.37%
-52.27
Total Capitalization
646.69
+238.13%
191.26
-20.69%
241.15
+561.37%
-52.27
Working Capital
646.27
+238.89%
190.71
-20.08%
238.62
+127.81%
104.74
Invested Capital
646.69
+238.13%
191.26
-20.69%
241.15
+561.37%
-52.27
Net Tangible Assets
646.69
+238.13%
191.26
-20.69%
241.15
+561.37%
-52.27
Tangible Book Value
646.69
+238.13%
191.26
-20.69%
241.15
+561.37%
-52.27
Preferred Stock Equity
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-142.42
+14.37%
-166.31
-104.89%
-81.17
-177.79%
-29.22
Cash Flow From Continuing Operating Activities
-142.42
+14.37%
-166.31
-104.89%
-81.17
-177.79%
-29.22
Net Income From Continuing Operations
-154.65
+13.02%
-177.81
-147.31%
-71.90
-141.28%
-29.80
Depreciation Amortization Depletion
0.06
+37.21%
0.04
0.00
—
Depreciation And Amortization
0.06
+37.21%
0.04
0.00
—
Other Non Cash Items
-9.88
-5.04%
-9.40
-37.00%
-6.87
-957.78%
-0.65
Stock Based Compensation
19.32
+70.47%
11.34
+124.03%
5.06
+1012.09%
0.46
Unrealized Gain Loss On Investment Securities
—
—
—
—
Change In Working Capital
2.73
-71.32%
9.52
+227.47%
-7.47
-1067.62%
0.77
Change In Receivables
-0.17
-139.15%
0.42
+219.44%
-0.35
0.00
Change In Prepaid Assets
2.47
-49.95%
4.93
+151.78%
-9.53
-325.45%
-2.24
Change In Payables And Accrued Expense
0.43
-89.74%
4.16
+72.38%
2.42
-19.82%
3.01
Investing Cash Flow
-389.75
-439.04%
114.96
+171.64%
-160.47
-637.50%
-21.76
Cash Flow From Continuing Investing Activities
-389.75
-439.04%
114.96
+171.64%
-160.47
-637.50%
-21.76
Net PPE Purchase And Sale
-0.01
+84.38%
-0.10
0.00
—
Purchase Of PPE
-0.01
+84.38%
-0.10
0.00
—
Capital Expenditure
-0.01
+84.38%
-0.10
—
—
Net Investment Purchase And Sale
-389.74
-438.74%
115.06
+171.70%
-160.47
-637.50%
-21.76
Purchase Of Investment
-814.74
-118.17%
-373.44
-7.32%
-347.97
-384.92%
-71.76
Sale Of Investment
425.00
-13.00%
488.50
+160.53%
187.50
+275.00%
50.00
Financing Cash Flow
591.00
+408.86%
116.14
-42.86%
203.25
+58.76%
128.02
Cash Flow From Continuing Financing Activities
591.00
+408.86%
116.14
-42.86%
203.25
+58.76%
128.02
Net Issuance Payments Of Debt
—
—
—
—
Issuance Of Debt
—
—
—
—
Short Term Debt Issuance
—
—
—
—
Net Short Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
578.36
+398.33%
116.06
-42.83%
202.99
+12561.02%
-1.63
Common Stock Payments
—
—
—
-1.63
Repurchase Of Capital Stock
—
—
—
-1.63
Proceeds From Stock Option Exercised
13.03
+2415.25%
0.52
+100.78%
0.26
0.00
Net Other Financing Charges
-0.39
+10.11%
-0.43
—
-1.63
Changes In Cash
58.83
-9.19%
64.79
+268.73%
-38.40
-149.84%
77.04
Beginning Cash Position
114.09
+131.40%
49.30
-43.78%
87.70
+722.56%
10.66
End Cash Position
172.92
+51.56%
114.09
+131.40%
49.30
-43.78%
87.70
Free Cash Flow
-142.43
+14.41%
-166.41
-105.01%
-81.17
-177.79%
-29.22
Common Stock Issuance
578.36
+398.33%
116.06
-42.83%
202.99
—
Issuance Of Capital Stock
578.36
+398.33%
116.06
-42.83%
202.99
+56.57%
129.65
Net Preferred Stock Issuance
—
—
0.00
-100.00%
129.65
Preferred Stock Issuance
—
—
0.00
-100.00%
129.65
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category